Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 1820237 + semaglutide
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
BI 1820237 + semaglutide is a combination therapy of a long-acting **neuropeptide Y2 receptor (NPY2R) agonist** (BI 1820237) and **semaglutide**, a glucagon-like peptide 1 receptor (GLP-1R) agonist. BI 1820237 is developed for obesity treatment and works by activating the NPY2R pathway to suppress food intake. Semaglutide is an established GLP-1R agonist that reduces appetite and body weight and has broad metabolic benefits. Preclinical and phase 1 studies indicate the combination leads to **synergistic anti-obesity effects**, with greater weight loss than either agent alone[1][3][5]. BI 1820237 is developed by Boehringer Ingelheim. Semaglutide is developed and manufactured by Novo Nordisk. The combination is under investigation, primarily for obesity and overweight/weight management, and has shown additive or synergistic efficacy in preclinical and early clinical trials[1][3][5][7][10].
- Other names
- BI 1820237 + semaglutide
02
Targets
NPY2R (Neuropeptide Y receptor subtype 2)GLP1R (GLP-1R)
Beyond the preview
Go deeper on BI 1820237 + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 1820237 + semaglutide.